Drug Sensitivity of Human Immunodeficiency Virus Type 1 Isolates after Ribavirin Therapy | Zendy

R Bernier | Zendy; Michel J. Tremblay | Zendy; Chris Tsoukas | Zendy; Michel G. Bergeron | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Sensitivity of Human Immunodeficiency Virus Type 1 Isolates after Ribavirin Therapy

Author(s) -

R Bernier,

Michel J. Tremblay,

Chris Tsoukas,

Michel G. Bergeron

Publication year - 1997

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/175.1.176

Subject(s) - ribavirin , virology , virus , drug , medicine , antiviral drug , viral disease , drug resistance , sida , human immunodeficiency virus (hiv) , immunology , biology , microbiology and biotechnology , pharmacology , hepatitis c virus

The antiviral agent ribavirin is effective against several virally induced diseases, and there is evidence that it might prove useful against human immunodeficiency virus type 1 (HIV-1) infection. Thus, there is interest in studying the resistance level of HIV-1 isolates to ribavirin following drug therapy. Low-passage clinical strains of HIV-1 were isolated from 3 patients undergoing treatment with ribavirin for 5-9 months. No significant changes in drug sensitivity were seen for sequential virus samples obtained before, during, and after antiviral therapy. These observations suggest that the appearance of a resistant phenotype is not induced by treatment with ribavirin in HIV-1-infected persons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research